Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reports on a recent think tank meeting on therapeutic HIV vaccines—these vaccines would attempt to control or eliminate the virus by prompting immune responses in HIV-positive people. Also in this issue is a brief report on the recent NIAID “mini-summit” on adenovirus platforms for HIV vaccines.
Px Wire October-December 2013, Vol. 6, No. 4
Px Wire July-September 2013, Vol. 6, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This quarter, Px Wire highlights three recent developments in the field and key issues for each: the World Health Organization (WHO) prequalification of PrePex, a nonsurgical voluntary medical male circumcision device; the positive result from the study of daily oral tenofovir as PrEP for HIV prevention in people who inject drugs; and new WHO guidelines on the use of ARVs, which recommend antiretroviral treatment for all HIV-positive people with CD4 cell counts of 500 or below.
Px Wire April-June 2013, Vol. 6, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of Px Wire highlights the adherence issues raised by the VOICE trial results and introduces a tool created to help civil society influence PEPFAR annual Country Operational Plans.
Px Wire January-March 2013, Vol. 6, No. 1
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reviews the recent AVAC Advocacy Partners’ Forum, where partners from across sub-Saharan Africa and beyond met and discussed goals for the year ahead. This issue also covers some key content and messages from the PEPFAR Blueprint.
Px Wire October-December 2012, Vol. 5, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of Px Wire features an advocates’ guide to the “sieve analysis” from the RV144 vaccine trial. This latest follow-up investigation provided further detail about the partial protection associated with the vaccine strategy. This issue also updates readers with the latest on trials of ARV-containing vaginal rings—the next frontier in microbicide development.
Px Wire July-September 2012, Vol. 5, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. As this issue of Px Wire went to press, the US Food and Drug Administration (FDA) announced its approval of daily oral TDF/FTC for PrEP. The issue reviews global PrEP developments and presents an infographic summarizing progress towards beginning to end the AIDS epidemic. In addition, this issue includes a list of prevention research-related sessions at AIDS 2012.
Too Little Too Slow: Results from from civil society monitoring of male circumcision for HIV prevention in Uganda
A jointly-authored report by Ugandan civil society groups taking stock of progress and challenges in Uganda’s voluntary medical male circumcision program as of 2012. Makes recommendations for future action, and highlights examples of best practices in the country.
GPP Blueprint for Stakeholder Engagement
The GPP Blueprint is a companion to the Good Participatory Practice guidelines for biomedical HIV prevention research. It is a step-by-step guide designed for the research team members in charge of stakeholder engagement. It presents questions, worksheets and explanations that can guide and generate a stakeholder engagement plan for a specific trial or research program.
Female-Initiated HIV Prevention: What will we learn from upcoming trials?
A 2007 document developed in anticipation of data from the Carraguard microbicide and MIRA diaphragm trials of women-initiated prevention strategies. It contains explanations of trial design and possible outcomes.
An Action Agenda to End AIDS: Critical actions from 2012-2016 to begin to end the HIV/AIDS pandemic
Released at AIDS 2012, this report lays out a plan for beginning to end HIV/AIDS. It includes clear time-bound outcome targets, as well as the responsibilities of different stakeholders to achieve these targets.